{"id":"escitalopram-venlafaxine","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-20","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Sweating"},{"rate":"5-10","effect":"Tremor"},{"rate":"3-5","effect":"Hypertension (venlafaxine component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram selectively inhibits serotonin reuptake at the presynaptic membrane, while venlafaxine inhibits reuptake of both serotonin and norepinephrine. Together, they increase synaptic concentrations of these monoamine neurotransmitters, which are thought to underlie their antidepressant and anxiolytic effects. This combination approach may provide broader neurochemical coverage than either agent alone.","oneSentence":"This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:44.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT05830279","phase":"","title":"Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-05-01","conditions":"Nausea With Vomiting Chemotherapy-Induced, Depression, Reactive, Cancer Pain","enrollment":600},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT00667121","phase":"","title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-03-16","conditions":"Breast Cancer, Depression, Hot Flashes","enrollment":88},{"nctId":"NCT04446039","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-04","conditions":"Major Depression","enrollment":370212},{"nctId":"NCT00200902","phase":"PHASE4","title":"Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Depression","enrollment":88},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05931965","phase":"NA","title":"Combination Therapy of Different Antidepressants With Dietary Supplements","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-05","conditions":"Depression","enrollment":88},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05777876","phase":"NA","title":"Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-01-01","conditions":"Treatment-Resistant Depression","enrollment":400},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT03294525","phase":"","title":"Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-01","conditions":"Affective Disorder","enrollment":400},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT04806230","phase":"","title":"Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study","status":"COMPLETED","sponsor":"Linkoeping University","startDate":"2011-04-01","conditions":"Pharmacokinetics, Antidepressive Agents, Pregnancy","enrollment":81},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT03522987","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Pilot Treatment Study","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05","conditions":"Anxiety, Depression, Epilepsy","enrollment":""},{"nctId":"NCT02711215","phase":"PHASE4","title":"Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-05","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT00386243","phase":"NA","title":"Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2007-12","conditions":"Low Back Pain, Pain, Pain, Intractable","enrollment":242},{"nctId":"NCT00854100","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-06-30","conditions":"Major Depressive Disorder","enrollment":231},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT00693849","phase":"PHASE4","title":"International Study to Predict Optimised Treatment - in Depression","status":"UNKNOWN","sponsor":"BRC Operations Pty. Ltd.","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":2688},{"nctId":"NCT02441387","phase":"","title":"Predictors of the Outcome of Late Life Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT01469377","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12-15","conditions":"Major Depressive Disorder","enrollment":819},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00057551","phase":"PHASE4","title":"Research Evaluating the Value of Augmenting Medication With Psychotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-04","conditions":"Depression, Depressive Disorder","enrollment":491},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT01658228","phase":"PHASE4","title":"Combination Treatment Study for Memory Impairment and Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-09","conditions":"Depression, Mild Cognitive Impairment","enrollment":86},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT00118430","phase":"PHASE4","title":"Stepped Care for Depression and Musculoskeletal Pain","status":"COMPLETED","sponsor":"Indiana University","startDate":"2004-09","conditions":"Pain, Depression","enrollment":500},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT02934035","phase":"","title":"Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2016-09","conditions":"Major Depressive Disorder","enrollment":10000},{"nctId":"NCT02873234","phase":"","title":"A Study of Chinese Medicine Treating Depression","status":"UNKNOWN","sponsor":"The Third Affiliated Hospital of Beijing University of Chinese Medicine","startDate":"2016-06","conditions":"Depression","enrollment":4600},{"nctId":"NCT02320240","phase":"","title":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-06","conditions":"Depression, Acute Kidney Injury","enrollment":3255526},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT00817011","phase":"NA","title":"Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2006-04","conditions":"Depression, Antidepressant Drug Adverse Reaction","enrollment":1000},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01796132","phase":"PHASE4","title":"Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-08","conditions":"Depressive Disorder, Lactation","enrollment":500},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47},{"nctId":"NCT00974155","phase":"PHASE4","title":"The Early Medication Change (EMC) Trial","status":"COMPLETED","sponsor":"K. Lieb","startDate":"2009-09","conditions":"Depression","enrollment":889},{"nctId":"NCT01436643","phase":"PHASE4","title":"Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Depression, Relapsing-remitting Multiple Sclerosis","enrollment":54},{"nctId":"NCT02237937","phase":"PHASE4","title":"Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene","status":"UNKNOWN","sponsor":"HolsboerMaschmeyer NeuroChemie GmbH","startDate":"2011-09","conditions":"Major Depression","enrollment":80},{"nctId":"NCT00074815","phase":"PHASE3","title":"Treatment of Obsessive Compulsive Disorder in Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-09","conditions":"Obsessive-Compulsive Disorder","enrollment":124},{"nctId":"NCT02179268","phase":"PHASE3","title":"Antidepressants and Bone Mineral Density","status":"COMPLETED","sponsor":"Guiyang Medical University","startDate":"2012-03","conditions":"Bone Mineral Density Quantitative Trait Locus 7","enrollment":203},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665},{"nctId":"NCT00018902","phase":"PHASE2, PHASE3","title":"Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2001-01","conditions":"Depression","enrollment":334},{"nctId":"NCT02012504","phase":"","title":"Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2013-06","conditions":"Adverse Drug Reaction, Anxiety Disorders and Symptoms","enrollment":50},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00177671","phase":"PHASE4","title":"Antidepressant Medication Plus Donepezil for Treating Late-life Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-12","conditions":"Depression, Dementia","enrollment":220},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080},{"nctId":"NCT00944996","phase":"NA","title":"Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression","status":"COMPLETED","sponsor":"Tirat Carmel Mental Health Center","startDate":"2009-06","conditions":"Major Depression","enrollment":100},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT01369290","phase":"","title":"Electroencephalography (EEG) Signal Processing","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2009-10","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT00351910","phase":"PHASE3","title":"Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Major Depressive Disorder","enrollment":494},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT00676039","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2007-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT00157547","phase":"PHASE4","title":"Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-04","conditions":"Major Depressive Disorder","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Escitalopram, venlafaxine","genericName":"Escitalopram, venlafaxine","companyName":"K. Lieb","companyId":"k-lieb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of escitalopram (an SSRI) and venlafaxine (an SNRI) increases serotonin and norepinephrine levels in the brain to treat depression and anxiety disorders. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}